# Single Ascending Dose Study of ALA-1000

> **NCT04122755** · PHASE1 · COMPLETED · sponsor: **Alar Pharmaceuticals Inc.** · enrollment: 59 (actual)

## Conditions studied

- Opioid-use Disorder

## Interventions

- **DRUG:** ALA-1000
- **DRUG:** buprenorphine sublingual film

## Key facts

- **NCT ID:** NCT04122755
- **Lead sponsor:** Alar Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-16
- **Primary completion:** 2021-05-03
- **Final completion:** 2021-05-03
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2021-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04122755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04122755, "Single Ascending Dose Study of ALA-1000". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04122755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*